(NASDAQ: TLPH) Talphera's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 365.63%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.81%.
Talphera's earnings in 2025 is -$12,388,000.On average, 4 Wall Street analysts forecast TLPH's earnings for 2025 to be -$16,639,634, with the lowest TLPH earnings forecast at -$15,987,099, and the highest TLPH earnings forecast at -$17,129,035. On average, 4 Wall Street analysts forecast TLPH's earnings for 2026 to be -$16,639,634, with the lowest TLPH earnings forecast at -$15,987,099, and the highest TLPH earnings forecast at -$17,129,035.
In 2027, TLPH is forecast to generate -$19,016,724 in earnings, with the lowest earnings forecast at -$18,270,970 and the highest earnings forecast at -$19,576,040.